Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G.
Gaut D, et al. Among authors: azenkot t.
Leuk Lymphoma. 2024 Jan;65(1):69-77. doi: 10.1080/10428194.2023.2264426. Epub 2024 Jan 10.
Leuk Lymphoma. 2024.
PMID: 37801340